Insomnia - 23/10/12
Doi : 10.1016/j.ncl.2012.08.012
Maryann C. Deak, MD ⁎ 
, John W. Winkelman, MD, PhD
, John W. Winkelman, MD, PhD Division of Sleep Medicine, Harvard Medical School, Sleep Health Centers, Brigham and Women's Hospital, 1505 Commonwealth Avenue, 5th Floor, Brighton, MA 02135, USA
Corresponding author.Resumen |
Insomnia is a common disorder, with individual and societal consequences. Advances have been made in the understanding of insomnia and its treatment options. However, cognitive behavioral therapy and Food and Drug Administration–approved pharmacologic therapies have limitations, the former primarily involving access and the latter involving potential side effects. Further research is needed to optimize management strategies.
El texto completo de este artículo está disponible en PDF.Keywords : Pharmacologic therapy, Cognitive behavioral therapy, For insomnia, Sleep disturbance
Esquema
© 2012
Elsevier Inc. Reservados todos los derechos.
Vol 30 - N° 4
P. 1045-1066 - novembre 2012 Regresar al número
Artículo precedente
- Hypersomnias of Central Origin
- Shelby F. Harris, Renee S. Monderer, Michael Thorpy
- Parasomnias and Their Mimics
- Raman K. Malhotra, Alon Y. Avidan
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?